je.st
news
Home
› Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
Sequella Acquires Exclusive Worldwide Rights To Pfizer's Sutezolid, Currently In Clinical Development For Tuberculosis
2013-07-17 04:00:00| drugdiscoveryonline Home Page
Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, recently announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis (TB)
Tags: rights
development
worldwide
exclusive
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||